Alvotech (NASDAQ:ALVO) Shares Gap Up – Here’s Why

Alvotech (NASDAQ:ALVO) gapped up prior to trading on Monday. The stock had previously closed at $5.45, but opened at $5.99. Alvotech shares last traded at $6.3060, with a volume of 1,151,506 shares.

Key Alvotech News

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: The FDA approved Alvotech’s application to manufacture AVT02, marketed in the U.S. as SIMLANDI®, in a second Reykjavik production suite. The approval effectively doubles U.S.-available drug-substance capacity, improves supply flexibility and supports potential growth in revenue from the Humira biosimilar. FDA approves additional U.S. manufacturing capacity for SIMLANDI
• Positive Sentiment: The regulatory decision further indicates that previous FDA inspection-related matters at the Reykjavik facility have been addressed. Investors may view this as reducing a key execution risk and improving the prospects for FDA action on pending applications for additional biosimilars, including proposed products targeting Simponi, Eylea, Prolia/Xgeva and Entyvio. Alvotech receives FDA approval to expand AVT02 manufacturing
• Positive Sentiment: Alvotech also entered a long-term manufacturing partnership with LOTTE Biologics. LOTTE will produce drug substance for multiple antibody biosimilars at its Syracuse, New York, facility, expanding Alvotech’s U.S. manufacturing footprint and global supply capacity. The site has 40,000 liters of bioreactor capacity and recently passed an FDA inspection with zero observations. Alvotech and LOTTE Biologics manufacturing agreement
• Neutral Sentiment: The announcements strengthen Alvotech’s manufacturing infrastructure but do not provide contract values, specific launch dates or near-term revenue guidance. The financial benefit will depend on product demand, commercialization by partners such as Teva and successful execution.
• Negative Sentiment: Commercial supply under the LOTTE agreement remains contingent on technology transfer, manufacturing qualification and additional regulatory approvals. The Reykjavik site’s prior FDA inspection received a Voluntary Action Indicated classification, so further compliance or regulatory delays remain possible.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ALVO. Barclays upgraded Alvotech from an “underweight” rating to an “overweight” rating and upped their price target for the company from $4.00 to $8.00 in a research report on Wednesday, September 16th. Weiss Ratings lowered shares of Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 17th. Evercore initiated coverage on shares of Alvotech in a research note on Friday, August 14th. They set an “outperform” rating for the company. Bank of America started coverage on shares of Alvotech in a report on Monday, August 24th. They set a “buy” rating and a $7.00 target price on the stock. Finally, UBS Group set a $8.00 target price on shares of Alvotech in a research note on Wednesday, September 16th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Alvotech Stock Up 0.5%

The company’s 50-day moving average is $4.90 and its two-hundred day moving average is $4.00. The company has a market capitalization of $1.85 billion, a P/E ratio of -10.07 and a beta of 0.20.

Alvotech (NASDAQ:ALVO) last announced its earnings results on Thursday, August 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.06). The business had revenue of $106.00 million for the quarter, compared to analyst estimates of $103.00 million. On average, sell-side analysts predict that Alvotech will post 0.01 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Alvotech stock. Citadel Advisors LLC purchased a new stake in shares of Alvotech (NASDAQ:ALVO) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,728,002 shares of the company’s stock, valued at approximately $6,376,000. Citadel Advisors LLC owned approximately 0.57% of Alvotech as of its most recent SEC filing.

About Alvotech

Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines. Biosimilars are biologic products designed to be highly similar to already approved reference medicines and are intended to expand access to treatments while supporting greater affordability.

The company’s pipeline includes biosimilar candidates for conditions in immunology, ophthalmology, oncology and other therapeutic areas. Its development activities cover complex biologic medicines, including treatments used for autoimmune and inflammatory diseases.